Last reviewed · How we verify
Kligman's Trio
Kligman's Trio, marketed by Centre Hospitalier Universitaire de Nice, holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging its established mechanism and indication. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Kligman's Trio |
|---|---|
| Sponsor | Centre Hospitalier Universitaire de Nice |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of a New Masterful Preparation to Kligman's Trio in the Treatment of Melasma (PHASE2)
- Treatment of Melasma With Stabilized Kligman Preparation Associated or Not With Pulsed Dye Laser (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kligman's Trio CI brief — competitive landscape report
- Kligman's Trio updates RSS · CI watch RSS
- Centre Hospitalier Universitaire de Nice portfolio CI